Opus Genetics Inc. (R3X1)
XFRA 
Summary
R3X1 Chart
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.32 per share a year ago.
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $1.27 per share a year ago.
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.29 per share a year ago.
Opus Genetics Inc. (R3X1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Opus Genetics Inc. ever had a stock split?
Opus Genetics Inc. Profile
| Biotechnology Industry | Healthcare Sector | George Magrath CEO | XFRA Exchange | US67577R1023 ISIN |
| US Country | 18 Employees | - Last Dividend | 6 Nov 2020 Last Split | - IPO Date |
Overview
Opus Genetics, Inc., initially known as Ocuphire Pharma, Inc., stands as a pioneering clinical-stage ophthalmic biopharmaceutical entity centered on the discovery, development, and commercialization of novel treatments aimed at addressing the unmet medical needs within the sphere of refractive and retinal eye disorders. Founded in 2018 and based in Farmington Hills, Michigan, the company dedicates its efforts to bridging the gap in care for patients suffering from a myriad of eye conditions, leveraging cutting-edge science to offer potential solutions.
Products and Services
- Phentolamine Ophthalmic Solution - This innovative solution is designed for the reversal of mydriasis and is currently under investigation in Phase III clinical trials for the treatment of presbyopia and challenges associated with dim light or night vision disturbances. The focus on such a broad spectrum of common yet often under-addressed eye conditions underscores the company's commitment to enhancing ocular health and patient well-being.
- APX3330 - As Opus Genetics, Inc.'s flagship retinal product candidate, APX3330 explores the therapeutic potential of a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. Having successfully completed Phase II clinical trials, APX3330 is positioned as a promising candidate for the treatment of diabetic retinopathy, a prevalent and debilitating condition that can lead to severe vision impairment.
- APX2009 and APX2014 - These preclinical product candidates signify the breadth of the company's research and development endeavors, with both aiming at combating retinal disorders. Although still in the preclinical stage, these candidates highlight Opus Genetics, Inc.'s relentless pursuit of novel solutions that could potentially revolutionize care for patients with retinal diseases.
